Search Results - "Kawaoka, T."

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 by Kosaka, K., Imamura, M., Hayes, C. N., Abe, H., Hiraga, N., Yoshimi, S., Murakami, E., Kawaoka, T., Tsuge, M., Aikata, H., Miki, D., Ochi, H., Matsui, H., Kanai, A., Inaba, T., Chayama, K.

“…Summary Daclatasvir (DCV) and asunaprevir (ASV) are NS5A and NS3 protease‐targeted antivirals respectively, currently under development for the treatment of…”
Get full text

Stress analysis in human temporomandibular joint affected by anterior disc displacement during prolonged clenching by Abe, S., Kawano, F., Kohge, K., Kawaoka, T., Ueda, K., Hattori-Hara, E., Mori, H., Kuroda, S., Tanaka, E.

“…Summary Parafunctional habits, such as prolonged clenching and bruxism, have been associated with dysfunctional overloading in the temporomandibular joint…”
Get full text

P-087A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer by Yoshino, S, Nishimura, T, Sakata, K, Yoshida, S, Furuya, T, Yamamoto, T, Kawaoka, T, Shimizu, R, Sato, T, Matoba, K, Morioka, H, Iida, M, Suzuki, N, Takeda, S, Ueno, T, Hazama, S, Nagano, H

Get full text

518 A multicenter prospective single-arm study to assess the predictive biomarkers of PSK responder from the analysis of cytokine promoter gene polymorphisms in patients with stage II or III colorectal cancer by Nishimura, T, Yoshino, S, Sakata, K, Furuya, T, Inoue, K, Saeki, T, Takemoto, K, Etoh, R, Kawaoka, T, Hasegawa, H, Kondo, H, Araki, A, Kudo, A, Hashimoto, K, Uchiyama, T, Yamamoto, T, Inoue, Y, Okayama, N, Hazama, S, Nagano, H

Get full text

Management bundles for candidaemia: the impact of compliance on clinical outcomes by Takesue, Y., Ueda, T., Mikamo, H., Oda, S., Takakura, S., Kitagawa, Y., Kohno, S., Masuda, A., Yoshida, C., Yasunaga, C., Yamashita, C., Nakataki, E., Ohyagi, H., Yagi, H., Johnai, H., Murai, H., Hanamoto, H., Nakamura, I., Sanada, I., Tandai, I., Kuroki, J., Ogawa, J., Kawahara, K., Amino, K., Nakajima, K., Yoshimoto, K., Takeda, K., Nakamura, K., Suzuki, K., Yamada, K., Aizawa, M., Hashimoto, M., Ogata, M., Shirano, M., Kawada, M., Kaneda, M., Yoshioka, M., Okuda, N., Sugita, N., Kikuchi, N., Fuke, S., Tsuchihashi, S., Sugitani, S., Ikuta, S., Honda, S., Nei, T., Iwamura, T., Yagi, T., Kaji, T., Ichimiya, Y., Kobayashi, Y., Minamishima, Y., Goto, Y., Hatano, Y., Nagao, Y., Yamagishi, Y., Sashihara, J., Tsukamoto, A., Kawaoka, T., Kobayashi, M.

Get full text

Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report by Kawaoka, T, Imamura, M, Kan, H, Fujino, H, Fukuhara, T, Kobayashi, T, Honda, Y, Naeshiro, N, Hiramatsu, A, Tsuge, M, Hayes, C.N, Kawakami, Y, Aikata, H, Ochi, H, Ishiyama, K, Tashiro, H, Ohdan, H, Chayama, K

“…Abstract We previously reported our data on telaprevir (TVR) used in combination with pegylated-interferon and ribavirin (PEG-IFN/RBV) for the treatment of…”
Get full text

Effects of the time interval between clamping and linear stapling for resection of porcine small intestine by Morita, K., Maeda, N., Kawaoka, T., Hiraki, S., Kudo, A., Fukuda, S., Oka, M.

“…Background Although a wait of several seconds after clamping is recommended when an automatic stapler is used to achieve adequate hemostasis, this wait has not…”
Get full text

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma by Kawaoka, T., Aikata, H., Takaki, S., Hiramatsu, A., Waki, K., Hiraga, N., Miki, D., Tsuge, M., Imamura, M., Kawakami, Y., Takahashi, S., Ochi, H., Tashiro, H., Ohdan, H., Chayama, K.

“…The present study was designed to determine the predictive factors for the viral response to pegylated interferon‐alpha plus ribavirin combination therapy…”
Get full text

P-141 Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced hepatocellular carcinoma by Yamauchi, M., Ono, A., Amioka, K., Fujii, Y., Uchikawa, S., Fujino, H., Nakahara, T., Murakami, E., Okamoto, W., Kawaoka, T., Miki, D., Tsuge, M., Imamura, M., Nelson, H., Kato, Y., Kimura, M., Suzuki, N., Aikata, H., Chayama, K.

Get full text

83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) by Chan, S.L., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Ran, D., Negro, A., Abou-Alfa, G.K.

Get full text

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) by Chan, S.L., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Gupta, C., Negro, A., Abou-Alfa, G.K.

Get full text

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) by Chan, L.S., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Ran, D., Negro, A., Abou-Alfa, G.K.

Get full text

Selective Incorporation of Influenza Virus RNA Segments into Virions by Fujii, Yutaka, Goto, Hideo, Watanabe, Tokiko, Yoshida, Tetsuya, Kawaoka, Yoshihiro

“…The genome of influenza A virus is comprised of eight viral RNA (vRNA) segments. Although the products of all eight vRNA segments must be present for viral…”
Get full text

P-087 A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer by Yoshino, S., Nishimura, T., Sakata, K., Yoshida, S., Furuya, T., Yamamoto, T., Kawaoka, T., Shimizu, R., Sato, T., Matoba, K., Morioka, H., Iida, M., Suzuki, N., Takeda, S., Ueno, T., Hazama, S., Nagano, H.

Get full text

Adoptive Immunotherapy for Pancreatic Cancer Using MUC1 Peptide-pulsed Dendritic Cells and Activated T Lymphocytes by KONDO, Hiroshi, HAZAMA, Shoichi, KAWAOKA, Toru, YOSHINO, Shigefumi, YOSHIDA, Shin, TOKUNO, Kazuhisa, TAKASHIMA, Motonari, UENO, Tomio, HINODA, Yuji, OKA, Masaaki

“…Background: Pancreatic cancer has a poor prognosis. The clinical efficacy of immunotherapy using both dendritic cells pulsed with MUC1 peptide (MUC1-DC) and,…”
Get full text

MUC1 Peptide Vaccination in Patients with Advanced Pancreas or Biliary Tract Cancer by YAMAMOTO, Kotaro, UENO, Tomio, HINODA, Yuji, KAWAOKA, Toru, HAZAMA, Shoichi, FUKUI, Mikiko, SUEHIRO, Yutaka, HAMANAKA, Yuichiro, IKEMATSU, Yoshito, IMAI, Kohzoh, OKA, Masaaki

“…Background: To evaluate the immunogenicity of MUC1 peptide vaccine in advanced pancreatic and bile duct cancers, a phase I clinical trial was conducted…”
Get full text

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma: PEGIFN/RBV after treatment for HCC by Kawaoka, T., Aikata, H., Takaki, S., Hiramatsu, A., Waki, K., Hiraga, N., Miki, D., Tsuge, M., Imamura, M., Kawakami, Y., Takahashi, S., Ochi, H., Tashiro, H., Ohdan, H., Chayama, K.

Get full text

Evolutional shape modeling by extended genetic algorithm: multi-step GA by Watabe, H., Kawaoka, T.

“…In a computer aided design (CAD) system, shape design or shape modeling is one often a bottleneck because shape design is a trial and error process often…”
Get full text

Application of multi-step GA to the traveling salesman problem by Watabe, H., Kawaoka, T.

“…Although GAs are widely used for optimization problems and often produce good results, there are also problems, such as premature convergence and evolutionary…”
Get full text

Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy by Kitamura, Shosuke, Tsuge, Masataka, Hatakeyama, Tsuyoshi, Abe, Hiromi, Imamura, Michio, Mori, Nami, Saneto, Hiromi, Kawaoka, Tomokazu, Mitsui, Fukiko, Hiraga, Nobuhiko, Takaki, Shintaro, Kawakami, Yoshiiku, Aikata, Hiroshi, Takahashi, Shoichi, Ohishi, Waka, Ochi, Hidenori, Hayes, C Nelson, Chayama, Kazuaki

“…The current standard therapy for chronic hepatitis C is pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Recently, it has been reported…”
Get more information